Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA wants a REMS for extended-release Zyprexa

Executive Summary

FDA will not approve Eli Lilly's long-acting version of its antipsychotic Zyprexa (olanzapine) without a Risk Evaluation and Mitigation Strategy, the agency says in a complete response letter. The depot version of the drug, which would be indicated for acute and maintenance treatment of schizophrenia in adults, has recently been approved in the EU and New Zealand. Although developing the REMS will not require a clinical trial, FDA's decision is another delay for the product. The agency had previously rejected the line extension, which had been using the tradename Zyprexa Adhera,in February 2008, saying it needed more information on the post-injection delirium and sedation observed in a small percentage of patients. Zyprexa, Lilly's top seller, loses patent protection in 2011
Advertisement

Related Content

Topics

Advertisement
UsernamePublicRestriction

Register

PS050529

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel